Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8kb to 5.0kb.
“Leveraging our Express Genes workflow, industry-leading error rate and rapid turnaround times, we continue to push the boundaries of what is possible in DNA synthesis to expand our portfolio of products that enable our customers to quickly and efficiently advance their research,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Our goal is to serve all researchers no matter where they are in their customer journey, whether they are Makers, Buyers or transitioning from Makers to Buyers. With the versatility, speed, high quality, scalability, competitive pricing, and now increased length of Twist Gene Fragments, we can further penetrate the Maker’s Market and meet the needs of customers who previously had to stitch together shorter fragments, as well as enable customers working in RNA therapeutic screening applications.”
Twist’s low error rate of 1:7,500 base pairs enables the production of longer fragments that can be easily incorporated into workflows, allowing researchers to select fewer colonies for screening or to use the gene fragments directly in in vitro transcription to make RNA. The increased length of the Gene Fragment gives researchers the ability to further customize and incorporate more elements into the fragment. Turnaround time for all Gene Fragments starts at two business days, regardless of length.
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
SOURCE: Businesswire